Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.

J Exp Clin Cancer Res · 2019 · PMC6827249 · PMID 31684985

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Regardless, the trial CheckMate-459 revealed a clear trend of improvement in OS for patients treated with opdivo compared to sorafenib, and exploration of opdivo in HCC will continue.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.